Inhibrx Biosciences, Inc.

US$84.52As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:INBXHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR 96.59%
Div yield —
ROE (1773.60%)
Biotechnology
Beta (5Y) 4.04
PE TTM —
TSR TTM 3.50%
Mkt cap US$1.244B
ROIC (90.13%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$94
11.22%
(14.87%)
Hold 5|11|7|9|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.10
1.09
1.07
1.14
1.65%
(7.36%)
(9.36%)
0.07%
Revenue$M
59.75
59.88
58.46
61.27
9.73%
8.19%
0.02%
3.21%
Peers (US$1.244B)
Cap (US$)
PE
1.227B
—
Capital
TTM
5Y
10Y
Leveragex
3.346
(0.162)
(0.121)
EBIT/Intx
2.659
0.097
0.092
Own earn%
(12.30)
94.49
101.28
Sh yield%
48.29
33.27
28.81
Owners
Insiders/Inst%
9.35
34.20
Short interest%
5.40
SBC / revenue%
1.84
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
0–3
$1 testx
0.1
Incr. ROIC%
7